Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS’ Predictive ...

Now, Chinese scientists have developed a kind of "double-sided tape" that helps the body's own soldiers — engineered immune cells — hold onto cancer cells more tightly, making treatment far more ...

SAN FRANCISCO--(BUSINESS WIRE)--Ossium Health, a clinical-stage bioengineering company that built a first-of-its-kind organ donor-derived bone marrow bank to deploy hematopoietic stem cells for blood ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...

Now, a step forward in genetic testing could help doctors look deeper than ever before to predict a patient's future health. In a series of studies published recently in Bone Marrow Transplantation, ...

Now, a research team from the Institute of Process Engineering (IPE) at the Chinese Academy of Sciences has developed a new helper molecule called FACE.

Bone marrow transplants can be life-saving for patients suffering from certain types of cancer, blood disorders and other diseases — but for many patients, finding a match can take months or years.

Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo ...

IN8bio, Inc. announced that 100% of acute myeloid leukemia (AML) patients treated with its allogeneic gamma-delta T cell therapy, INB-100, remain in complete remission (CR) with a median follow-up of ...